These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 27671847

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Human graft-derived mesenchymal stromal cells potently suppress alloreactive T-cell responses.
    de Mare-Bredemeijer EL, Mancham S, Verstegen MM, de Ruiter PE, van Gent R, O'Neill D, Tilanus HW, Metselaar HJ, de Jonge J, Kwekkeboom J, Hall SR, van der Laan LJ.
    Stem Cells Dev; 2015 Jun 15; 24(12):1436-47. PubMed ID: 25744002
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. B7‑H1‑mediated immunosuppressive properties in human mesenchymal stem cells are mediated by STAT‑1 and not PI3K/Akt signaling.
    Jang IK, Jung HJ, Noh OK, Lee DH, Lee KC, Park JE.
    Mol Med Rep; 2018 Aug 15; 18(2):1842-1848. PubMed ID: 29901104
    [Abstract] [Full Text] [Related]

  • 25. Human umbilical cord-derived mesenchymal stem cells suppress proliferation of PHA-activated lymphocytes in vitro by inducing CD4(+)CD25(high)CD45RA(+) regulatory T cell production and modulating cytokine secretion.
    Yang H, Sun J, Li Y, Duan WM, Bi J, Qu T.
    Cell Immunol; 2016 Apr 15; 302():26-31. PubMed ID: 26774852
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells.
    Aboulkheyr Es H, Bigdeli B, Zhand S, Aref AR, Thiery JP, Warkiani ME.
    J Cell Physiol; 2021 May 15; 236(5):3918-3928. PubMed ID: 33145762
    [Abstract] [Full Text] [Related]

  • 28. Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling.
    Mokarizadeh A, Delirezh N, Morshedi A, Mosayebi G, Farshid AA, Mardani K.
    Immunol Lett; 2012 Sep 15; 147(1-2):47-54. PubMed ID: 22705267
    [Abstract] [Full Text] [Related]

  • 29. Immunomodulatory properties of colonic mesenchymal stem cells.
    Hu J, Zhang X, Zhou L, Zhang Y.
    Immunol Lett; 2013 Sep 15; 156(1-2):23-9. PubMed ID: 24060593
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.
    Jalali S, Price-Troska T, Paludo J, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Ansell SM.
    Blood Adv; 2018 Aug 14; 2(15):1985-1997. PubMed ID: 30104397
    [Abstract] [Full Text] [Related]

  • 34. Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells.
    Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L, You Z.
    Immunol Lett; 2017 Apr 14; 184():7-14. PubMed ID: 28223102
    [Abstract] [Full Text] [Related]

  • 35. Human amnion-derived mesenchymal stem cells attenuate xenogeneic graft-versus-host disease by preventing T cell activation and proliferation.
    Tago Y, Kobayashi C, Ogura M, Wada J, Yamaguchi S, Yamaguchi T, Hayashi M, Nakaishi T, Kubo H, Ueda Y.
    Sci Rep; 2021 Jan 28; 11(1):2406. PubMed ID: 33510297
    [Abstract] [Full Text] [Related]

  • 36. PD-L1 overexpression conveys tolerance of mesenchymal stem cell-derived cardiomyocyte-like cells in an allogeneic mouse model.
    Mardomi A, Limoni SK, Rahbarghazi R, Mohammadi N, Khorashadizadeh M, Ranjbaran H, Nataj HH, Jafari N, Hasani B, Abediankenari S.
    J Cell Physiol; 2021 Sep 28; 236(9):6328-6343. PubMed ID: 33507552
    [Abstract] [Full Text] [Related]

  • 37. Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1/PD-L1 axis.
    He Y, Qu Y, Meng B, Huang W, Tang J, Wang R, Chen Z, Kou X, Shi S.
    Cell Death Dis; 2022 Apr 18; 13(4):365. PubMed ID: 35436982
    [Abstract] [Full Text] [Related]

  • 38. Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
    Singh A, Mohan A, Dey AB, Mitra DK.
    Clin Exp Immunol; 2017 Feb 18; 187(2):269-283. PubMed ID: 27665733
    [Abstract] [Full Text] [Related]

  • 39. Human mesenchymal stem cells from adipose tissue and amnion influence T-cells depending on stimulation method and presence of other immune cells.
    Kronsteiner B, Wolbank S, Peterbauer A, Hackl C, Redl H, van Griensven M, Gabriel C.
    Stem Cells Dev; 2011 Dec 18; 20(12):2115-26. PubMed ID: 21381973
    [Abstract] [Full Text] [Related]

  • 40. An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
    Khedri M, Abnous K, Rafatpanah H, Ramezani M.
    J Recept Signal Transduct Res; 2018 Feb 18; 38(1):31-36. PubMed ID: 29252078
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.